{
  "meta": {
    "title": "Plasma_Chemical_Mediators",
    "url": "https://brainandscalpel.vercel.app/plasma-chemical-mediators-1b13be7f.html",
    "scrapedAt": "2025-11-29T18:32:15.473Z"
  },
  "questions": [
    {
      "id": 14083,
      "choices": [
        {
          "id": 56293,
          "text": "<p><span style=\"font-size:12pt;\">Systemic lupus erythematosus (SLE)</span></p>"
        },
        {
          "id": 56294,
          "text": "<p><span style=\"font-size:12pt;\">Multiple sclerosis (MS)</span></p>"
        },
        {
          "id": 56295,
          "text": "<p><span style=\"font-size:12pt;\">Hereditary angioedema (HAE)</span></p>"
        },
        {
          "id": 56296,
          "text": "<p><span style=\"font-size:12pt;\">Psoriasis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following diseases is associated with an over-activation in the complement pathway?</span></p>",
      "unique_key": "Q8057868",
      "question_audio": null,
      "question_video": null,
      "map_id": 31744,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Hereditary angioedema</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Hereditary angioedema </strong>is a rare <strong>genetic disorder </strong>that is caused by a <strong>deficiency or dysfunction of C1 inhibitor,</strong> a protein involved in the <strong>complement pathway</strong>. This defect leads to <strong>uncontrolled activation of the complement pathway</strong>, resulting in excessive release of <strong>bradykinin, </strong>which causes <strong>recurrent episodes of swelling in various parts of the body.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Hereditary Angioedema (HAE)</strong> is a<strong> genetic disorder </strong>due to a deficiency or dysfunction of the <strong>C1 inhibitor (C1-INH), </strong>which normally regulates the<strong> complement and contact systems</strong>. The lack of functional<strong> C1-INH leads to uncontrolled activation of the complement </strong>pathway, excessive production of<strong> bradykinin</strong>, and<strong> recurrent episodes of swelling.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.&nbsp;Systemic Lupus Erythematosus (SLE):&nbsp;</strong>SLE is an<strong> autoimmune disease </strong>characterized by the production of autoantibodies that form<strong> immune complexes. </strong>These complexes can <strong>trigger the complement system</strong>, often leading to <strong>complement depletion</strong>. It is not typically associated with an over-activation of the complement pathway.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.&nbsp;Multiple Sclerosis (MS):&nbsp;</strong>MS is a<strong> chronic autoimmune, inflammatory neurological disease </strong>that primarily affects the <strong>central nervous system</strong>. The complement system<strong> may play a role in the pathology of MS</strong>; however, it is not characterized by over-activation of the complement pathway.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;Psoriasis is a <strong>chronic inflammatory skin disease </strong>with a complex pathogenesis involving the<strong> immune system</strong>. While the <strong>complement system </strong>may be<strong> activated </strong>as part of the <strong>inflammatory process in psoriasis</strong>, the disease is not primarily associated with an over-activation of the complement pathway.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>HAE </strong>is associated with<strong> over-activation </strong>of the <strong>complement pathway </strong>due to <strong>C1 inhibitor deficiency</strong>, leading to excessive<strong> bradykinin release </strong>and<strong> recurrent angioedema.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">HAE:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Autosomal dominant disease</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>C1-INH</strong> normally stops spontaneous activation of:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">C1 (classical pathway)</span></li><li><span style=\"font-size:12.0pt;\">Kallikrein → which generates bradykinin</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Without C1-INH:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\"><strong>Classical pathway is continuously activated</strong> → consumes complement (↓ C4, ↓ C2)</span></li><li><span style=\"font-size:12.0pt;\">Over-production of <strong>bradykinin</strong> → vasodilation, edema</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Clinically → patients have recurrent <strong>non-pitting angioedema</strong> (face, extremities, GI tract → can cause severe abdominal pain)</span></p>",
      "correct_choice_id": 56295,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14106,
      "choices": [
        {
          "id": 56385,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C1 </span></span></span></p>"
        },
        {
          "id": 56386,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C2 </span></span></span></p>"
        },
        {
          "id": 56387,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C3 </span></span></span></p>"
        },
        {
          "id": 56388,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C4</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following complement component can be activated is both common as well as alternative pathways? </span></span></p>",
      "unique_key": "Q4785948",
      "question_audio": null,
      "question_video": null,
      "map_id": 31743,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) C3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> complement proteins </strong>can be activated by 3 pathways; <strong>classical, lectin and alternate pathways</strong>. <strong>Terminal pathway is common to the first three pathways </strong>and is present at the level o<strong>f post activation stage of C3</strong>. It eventually leads to the <strong>membrane attack complex that lyses cells</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C3</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>central component </strong>of the<strong> complement system </strong>and can be <strong>activated </strong>by all three pathways: <strong>classical, lectin, and alternative. </strong>The cleavage oF&nbsp;<strong>C3 into C3a and C3b </strong>is a crucial step in the<strong> activation of the complement system.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. C1</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>first component </strong>of the classical pathway of<strong> complement activation</strong>. It is <strong>not </strong>involved in the <strong>alternative pathway</strong>, which is initiated by spontaneous<strong> hydrolysis or microbial surface constituents</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. C2</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is part of the <strong>classical and lectin pathways</strong>. It forms a<strong> complex with C4 </strong>to produce the <strong>C3 convertase C4b2a</strong>. C2 is not involved in the alternative pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. C4</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is involved in the <strong>classical and lectin pathways </strong>where, along <strong>with C2</strong>, it forms the <strong>C3 convertase</strong>. It is not part of the alternative pathway, which <strong>bypasses C4</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>C3 </strong>is a key component in the <strong>complement system </strong>that is activated by all three pathways:<strong> classical, lectin, and alternative. </strong>Its activation is pivotal in the <strong>complement-mediated immune response</strong>, including<strong> opsonization </strong>and <strong>formation of the membrane attack complex. </strong></span></span></span></p>",
      "correct_choice_id": 56387,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}